Medtronic plc (MDT) is a global medical technology company with a market cap of around $132 billion, specializing in device-based therapies for various health conditions like cardiovascular, neuroscience, medical-surgical, and diabetes care.

Although MDT stock has lagged behind the market over the past 52 weeks, it has shown a 7.3% YTD return, outperforming the broader market like the S&P 500 Index and the State Street Health Care Select Sector SPDR ETF.

Medtronic’s stock rose 4.7% on Nov. 18, 2025, following strong Q2 2026 results, including adjusted EPS of $1.36, revenue of $8.96 billion, and a 6.6% revenue growth. The company also raised its 2026 guidance with expected organic revenue growth of ~5.5% and adjusted EPS of $5.62 – $5.66.

For the fiscal year ending in April 2026, analysts predict MDT’s adjusted EPS to grow 2.7% YoY to $5.64, with a promising earnings surprise history, consistently beating consensus estimates in the last four quarters.

Despite a less bullish consensus rating of “Moderate Buy” from 27 analysts, Evercore ISI raised Medtronic’s price target to $115 on Nov. 18, 2025, with a mean price target of $110.50, representing a 7.5% premium to current price levels, and a high target of $125, suggesting a potential upside of 21.6%.

Read more at Yahoo Finance: Are Wall Street Analysts Predicting Medtronic Stock Will Climb or Sink?